Targeted radiation for lymph node recurrence after prostate cancer treatment
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a precise type of radiation therapy (called SABR) for prostate cancer that has returned in the lymph nodes only. It aims to control the cancer with fewer side effects and might offer a treatment option when surgery or other standard treatments are no longer enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have prostate cancer that has come back in the lymph nodes (pelvis or abdomen) after initial treatment, confirmed by a special PET/CT scan.
- The cancer in the lymph nodes is small (each 2 cm or less).
- Any other areas of cancer (outside the target nodes) must be treatable with ablative therapy (like focused radiation).
- Your life expectancy is more than 6 months.
- You do not have any medical conditions that prevent you from having an MRI or radiation therapy (like active inflammatory bowel disease in the pelvis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.
This Phase 2 study tests a treatment plan that uses standard focused radiation to the prostate, plus an extra “boost” delivered inside the prostate. It may help improve control of high-risk prostate cancer, especially by aiming radiation more precisely.
This trial studies the use of radiation to the prostate and to all visible spots where cancer has spread, in men who have up to 10 small areas of spread when first diagnosed. The goal is to see if this approach can help control the cancer.
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
This trial tests a high-precision, short-course radiation treatment for prostate cancer that has spread to a few lymph nodes in the pelvis. The treatment uses weekly MRI or CT scans to adapt the radiation to your exact anatomy, aiming to target the cancer while protecting healthy tissue.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.